Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aurobindo Pharma's share price for the quarter that ended in Mar. 2026 was ₹1303.2. Aurobindo Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 581 Mil. Therefore, Aurobindo Pharma's market cap for the quarter that ended in Mar. 2026 was ₹756,901 Mil.
Aurobindo Pharma's quarterly market cap
increased
from Sep. 2025 (₹629,502 Mil) to Dec. 2025 (₹686,043 Mil) and
increased
from Dec. 2025 (₹686,043 Mil) to Mar. 2026 (₹756,901 Mil).
Aurobindo Pharma's annual market cap
increased
from Mar. 2024 (₹638,351 Mil) to Mar. 2025 (₹673,556 Mil) and
increased
from Mar. 2025 (₹673,556 Mil) to Mar. 2026 (₹756,901 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aurobindo Pharma's Enterprise Value for Today is ₹873,756 Mil.
Aurobindo Pharma (BOM:524804) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aurobindo Pharma Market Cap Related Terms
Aurobindo Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aurobindo Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurobindo Pharma (BOM:524804) has a Market Cap of ₹900,294 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aurobindo Pharma and its competitors. According to the industry distribution chart, Aurobindo Pharma ranks #54 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Aurobindo Pharma's Market Cap too high?
Aurobindo Pharma's current Market Cap is ₹900,294 Mil. Based on the distribution chart, Aurobindo Pharma ranks #54 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aurobindo Pharma has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #54 out of 1024 companies for Market Cap. This places Aurobindo Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.52, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current Market Cap is ₹900,294 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,333.66, compared to a current price of ₹1,564.65 — trading 17.3% above its estimated fair value. The current Market Cap is ₹900,294 Mil. Aurobindo Pharma's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Market Cap is ₹900,294 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,564.65 is trading 17.3% above its estimated GF Value™ of ₹1,333.66.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
Market Cap: ₹900,294 Mil
GF Value™: ₹1,333.66 vs. price of ₹1,564.65 (17.3% above fair value)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
88GF Score
Get the complete analysis for BOM:524804
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
